|
AU2005312402A1
|
|
Methods using mitochondrial nucleic acid for determining a health status of an individual
|
|
WO2006038797A1
|
|
Use of statin or precursor thereof for the treatment of hiv infections
|
|
EP1746102A1
|
|
Parechovirus, vaccines, medicaments and diagnostic kits
|
|
EP1652935A1
|
|
Methods using mitochondrial nucleic acid for determining a health status of an individual
|
|
EP1658845A1
|
|
Use of statin or precursor thereof for the treatment of virusinfections
|
|
EP1571225A1
|
|
Diagnosis of a disease and monitoring of therapy using the AC133 gene
|
|
WO2004042085A2
|
|
Method for quantifying a ratio between at least two nucleic acid sequences
|
|
EP1418242A1
|
|
Method for quantifying a ratio between at least two nucleic acid sequences
|
|
EP1493823A1
|
|
HMG coenzyme A reductase inhibitors affect the mitochondrial DNA content of cells
|
|
EP1479761A1
|
|
New enterovirus, vaccines, medicaments and diagnostic kits
|
|
EP1418241A1
|
|
Method for quantifying a ratio between at least two nucleic acid sequences
|
|
EP1378576A1
|
|
Storing and detecting nucleic acid administered to a solid carrier
|
|
IL156286D0
|
|
Testing endosymbiont cellular organelles and compounds identifiable therewith
|
|
EP1298221A1
|
|
Means and methods for treatment evaluation
|
|
US6750014B2
|
|
Reducing background in hybridization reactions
|
